SCHEMBL3710474

SCHEMBL3710474

Cc1ccnc2c(-c3cccc(Cl)c3)c(NC(=O)CCc3ccccc3)nn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.47
TP53 P04637 1/20 0.45
THRB P10828 1/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ADORA3 P0DMS8 1/20 0.41
POLB P06746 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
MAPT P10636 2/20 0.40
GAA P10253 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KCNQ3 O43525 2/20 0.39
KCNQ2 O43526 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707258 0.80 MAPK14 (0.48) THRBMEN1KMT2ALMNATSHR
SCHEMBL3705325 0.76 KCNQ3 (0.54) HCAR2TP53THRBMEN1KMT2A
SCHEMBL3703282 0.75 KCNQ3 (0.56) HCAR2MEN1KMT2ALMNASMN1; SMN2
SCHEMBL3702148 0.74 KCNQ3 (0.52) MEN1KMT2ALMNASMN1; SMN2POLB
SCHEMBL3700376 0.74 KCNQ2 (0.55) TP53MEN1KMT2AMAPTNPC1
SCHEMBL3707943 0.74 KCNQ3 (0.43) TP53KMT2ASMN1; SMN2MAPTGAA
SCHEMBL3698581 0.73 KCNQ3 (0.67) HCAR2MEN1KMT2AALOX15LMNA
SCHEMBL3700928 0.72 KCNQ3 (0.72) RAB9AKCNQ3KCNQ2
SCHEMBL3708798 0.72 KCNQ3 (0.56) HCAR2TP53THRBMEN1KMT2A
SCHEMBL3700999 0.72 KCNQ3 (0.54) HCAR2TP53MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US claimed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO claimed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US disclosed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO disclosed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122888-A1 Potassium Channel Modulators KCNQ1, KCNQ2, KCNJ2 HCAR2 855/4885TP53 4587/4885THRB 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.